Clinical trial
Dose-sparing Balanced Propofol Analgosedation for Colonoscopy: a Randomized Controlled Trial of a Structured Sedation Protocol
NCT07885059 is registered in ClinicalTrials.gov with University of Split, School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dose-sparing Balanced Propofol Analgosedation for Colonoscopy: a Randomized Controlled Trial of a Structured Sedation Protocol
- Lead sponsor
- University of Split, School of Medicine
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- June 5, 2022
- Completion date
- February 8, 2024
- Enrollment
- 76 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
colonoscopy, sedation and analgesia
Arms
As registered; 2 arms.
-
Standard-dose balanced propofol analgosedation
Intravenous midazolam 0.05 mg/kg (maximum 5 mg), followed by fentanyl 0.001 mg/kg and an initial propofol bolus of 1.0 mg/kg. Additional propofol boluses of 10-30 mg were administered according to clinical need. Sedation and monitoring were guided by an anesthesiologist with an anesthesia technician present.
-
Dose-sparing balanced propofol analgosedation
Intravenous midazolam 0.05 mg/kg (maximum 5 mg), followed by fentanyl 0.001 mg/kg and an initial propofol bolus of 0.5 mg/kg. Additional propofol boluses of 10-30 mg were administered according to clinical need. Sedation and monitoring were guided by a gastroenterologist trained in advanced life support and airway management, with an anesthesia technician present and an anesthesiologist immediately available if required.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Patient satisfaction
Patient satisfaction was assessed using a study-specific four-item questionnaire. Two items assessed satisfaction with the colonoscopy procedure and satisfaction with analgosedation using separate 11-point numerical rating scales ranging from 0 (completely dissatisfied) to 10 (extremely satisfied). Two additional binary items assessed whether the participant would recommend the same approach to relatives or friends and whether the participant would agree to undergo colonoscopy using the same approach again.
-
Incidence of clinically relevant respiratory adverse events
Incidence of protocol-defined respiratory adverse events, reported by event type. Respiratory events included apnea lasting more than 30 seconds, oxygen saturation below 90%, respiratory rate below 10 or above 20 breaths per minute, end-tidal CO2 below 35 mmHg, and the need for airway-opening interventions. Apnea lasting more than 30 seconds was analyzed as the principal respiratory safety endpoint.
Lead sponsor's other trials
University of Split, School of Medicine, most recent start first.
+45 more trials See the organization page
Similar trials
Same condition (Agnosia) and phase, most recent start first.
+1,650 more trials See the condition page